SaNOtize moves to carve a new market demand: over-the-counter prevention
There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October.
As a result, the company is pivoting, exploring the use of the spray as a preventative treatment, which, if successful, would be pursued as a direct over-the-counter med.
“There is no monograph right now for OTC antivirals—it doesn’t exist,” SaNOtize CEO Gilly Regev, Ph.D., said in an interview. “So it's a little bit of paving your own path, like we always need to do with nitric oxide. So it doesn't scare us.”
Published by Max Bayer Jul 25, 2022 11:37am